Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell receptors (BCRs) and antibodies specific for H1 hemagglutinin (HA) and N1 neuraminidase (NA) are the primary mediators of adaptive immunity against H1N1 influenza A viruses. Hemagglutinin is a surface glycoprotein that facilitates viral entry by binding to host cell sialic acid receptors, while neuraminidase is an enzyme required for the release of new viral particles from the cell surface (Nature, 2009, 459:1122-1125). Antibodies targeting the H1 head domain provide potent, strain-specific neutralization, whereas those targeting the conserved H1 stem or the N1 active site often provide broader protection across different H1N1 variants (Science, 2011, 333:850-856). These immunological components are the central targets of seasonal and pandemic influenza vaccines, which aim to elicit protective titers to prevent infection and reduce disease severity (The Lancet, 2012, 379:1413-1424). In addition to active immunization, monoclonal antibodies (mAbs) directed against these antigens are being developed as passive immunotherapies for severe influenza, offering a potential alternative when small-molecule antivirals like oseltamivir face resistance (Journal of Clinical Investigation, 2015, 125:125-131). Monitoring the specificity and durability of these B-cell responses is essential for the design of next-generation universal influenza vaccines.
Antibodies bind to the globular head or stem region of H1 hemagglutinin to block viral attachment to sialic acid receptors and prevent membrane fusion, or bind to the active site of N1 neuraminidase to inhibit the enzymatic cleavage of sialic acid, thereby preventing the release of progeny virions from infected host cells (Nature, 2009, 459:1122-1125; Science, 2011, 333:850-856).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell receptors and antibodies specific for H1 hemagglutinin and N1 neuraminidase (H1N1-specific BCRs/Abs).